SEARCH

SEARCH BY CITATION

References

  • 1
    Matthews A. Nonulcerative keratopathies in the horse. Equine Veterinary Education 2000; 12: 271278.
  • 2
    Gilger BC, Michau TM, Salmon JH. Immune-mediated keratitis in horses: 19 cases (1998–2004). Veterinary Ophthalmology 2005; 8: 233239.
  • 3
    Pate DO, Clode AB, Olivry T et al. Immunohistochemical and immunopathologic characterization of superficial stromal immune-mediated keratitis in horses. American Journal of Veterinary Research 2012; 73: 10671073.
  • 4
    Matthews A, Gilger BC. Equine immune-mediated keratopathies. Veterinary Ophthalmology 2009; 12(Suppl 1): 1016.
  • 5
    Matthews A, Gilger BC. Equine immune-mediated keratopathies. Equine Veterinary Journal 2010; 42(Suppl 37): 3137.
  • 6
    Pinto N, McMullen R, Linder K et al. Pigmentary keratouveitis in horses. International Equine Ophthalmology Consortium Symposium, Jackson Hole, Wy. June 9, 2013. Abstract.
  • 7
    Gilger BC, Malok E, Stewart T et al. Effect of an intravitreal cyclosporine implant on experimental uveitis in horses. Veterinary Immunology and Immunopathology 2000; 76: 239255.
  • 8
    Kim H, Csaky KG, Gilger BC et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Investigative Ophthalmology & Visual Science 2005; 46: 655662.
  • 9
    Acton AE, Beale AB, Gilger BC et al. Sustained release cyclosporine therapy for bilateral keratoconjunctivitis sicca in a red wolf (Canis rufus). Journal of Zoo and Wildlife Medicine 2006; 37: 562564.
  • 10
    Gilger BC, Salmon JH, Wilkie DA et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Investigative Ophthalmology & Visual Science 2006; 47: 25962605.
  • 11
    Lee SS, Kim H, Wang NS et al. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Investigative Ophthalmology & Visual Science 2007; 48: 20232029.
  • 12
    Chang-Lin JE, Burke JA, Peng Q et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Investigative Ophthalmology & Visual Science 2011; 52: 46054609.
  • 13
    Ghosn CR, Li Y, Orilla WC et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Investigative Ophthalmology & Visual Science 2011; 52: 29172923.
  • 14
    Lowder C, Belfort R Jr, Lightman S et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Archives of Ophthalmology 2011; 129: 545553.
  • 15
    Robinson MR, Whitcup SM. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Review of Clinical Pharmacology 2012; 5: 629647.
  • 16
    Barachetti L, Rampazzo A, Mortellaro CM et al. Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca (Abstract). American College of Veterinary Ophthalmologists. November 2013; Puerto Rico.
  • 17
    Gilger BC, Reeves KA, Salmon JH. Ocular parameters related to drug delivery in the canine and equine eye: aqueous and vitreous humor volume and scleral surface area and thickness. Veterinary Ophthalmology 2005; 8: 265269.
  • 18
    Gilger BC, Stoppini R. Equine ocular examination: routine and advanced diagnostic techniques. In: Equine Ophthalmology, 2nd edn. (ed. Gilger BC) Elsevier, Philadelphia, 2011; 151.
  • 19
    Plummer CE, Ollivier F, Kallberg M et al. The use of amniotic membrane transplantation for ocular surface reconstruction: a review and series of 58 equine clinical cases (2002–2008). Veterinary Ophthalmology 2009; 12(Suppl 1): 1724.
  • 20
    Theng J, Zhou L, Tan D et al. Distribution of cyclosporine A in the cornea after topical or oral administration. Journal of Ocular Pharmacy 2002; 18: 8388.
  • 21
    Jain K, Kumar RS, Sood S et al. Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy. Current Drug Delivery 2013; 12: 332336.
  • 22
    Robbie SJ, Lundh von Leithner P, Ju M et al. Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. Investigative Ophthalmology & Visual Science 2013; 54: 14901500.
  • 23
    Musumeci T, Bucolo C, Carbone C et al. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. International Journal of Pharmaceutics 2013; 440: 135140.